Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of Enpatoran in Healthy Men
NCT05110027Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enpatoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), sponsored by Merck KGaA. Primary endpoints: Percent Urinary Recovery of Total Radioactivity, Percent Fecal Recovery of Total Radioactivity and 4 more. Started Nov 2021; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05110027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110027.